CULT Food Science’s portfolio company to scale-up cell manufacturing process for cellular aquaculture
by CM Staff
CELL AG is to collaborate with CCRM and its team of experts to develop a cost-effective and efficient manufacturing process for fish cells in bioreactors.
VANCOUVER — CULT Food Science Corp., an investment platform with a focus on cellular agriculture that is advancing the development of novel technologies to provide a sustainable and environmental solution to the global factory farming and aquaculture crises, announces that its portfolio company, CELL AG TECH, has signed an agreement with the Centre for Commercialization of Regenerative Medicine to scale-up its cell manufacturing process for cell-based fish products.
Located in Toronto, Ontario, CCRM is involved in developing and commercializing regenerative medicine-based technologies and cell and gene therapies. Additionally, the Portfolio Company was announced as a winner of the AcCELLerate-ON competition for its scaling-up of the manufacturing of fish muscle stem cells from a 2D to 3D culture system including proteomic assessments of the cells.
CELL AG is to collaborate with CCRM and its team of experts to develop a cost-effective and efficient manufacturing process for fish cells in bioreactors. CCRM’s experience in cell manufacturing will serve to apply principles developed for regenerative medicine to cellular agriculture and will efficiently accelerate the Portfolio Company’s product development process.
The scalability of cell-based fish in the cellular agriculture sector is still a work in progress, but it is believed that cultured fish could become quite popular due to the overwhelming issues that traditional fish production creates such as illegal fishing and overfishing, warming ocean temperatures, ocean acidification, animal welfare and concerns about food waste.
CCRM is a global, public-private partnership headquartered in Canada. It receives funding from the Government of Canada, the Province of Ontario and leading academic and industry partners. CCRM reportedly supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of researchers, leading companies, investors and entrepreneurs, CCRM is trying to accelerate the translation of scientific discovery into new companies and infrastructure.
